Therapeutic potential of oncolytic measles virus

Promises and challenges

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)620-625
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

Oncolytic Viruses
Measles virus
Bystander Effect
Measles Vaccine
Neoplasms
RNA Viruses
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Therapeutic potential of oncolytic measles virus : Promises and challenges. / Galanis, Evanthia.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 5, 11.2010, p. 620-625.

Research output: Contribution to journalArticle

@article{adad6a23818b40ec970b74b4dedde94b,
title = "Therapeutic potential of oncolytic measles virus: Promises and challenges",
abstract = "Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.",
author = "Evanthia Galanis",
year = "2010",
month = "11",
doi = "10.1038/clpt.2010.211",
language = "English (US)",
volume = "88",
pages = "620--625",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Therapeutic potential of oncolytic measles virus

T2 - Promises and challenges

AU - Galanis, Evanthia

PY - 2010/11

Y1 - 2010/11

N2 - Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.

AB - Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=77958501444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958501444&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.211

DO - 10.1038/clpt.2010.211

M3 - Article

VL - 88

SP - 620

EP - 625

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -